Jenburkt Pharma Peer Comparison

BSE: 524731

₹1,051.20

₹3.20 (0.31%)

As on 31-Aug-2026IST

Market cap

₹464 Cr

Revenue (TTM)

₹169 Cr

P/E Ratio

14.1

P/B Ratio

2.3

Div. Yield

2 %

Edit

	Jenburkt Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	464	30,606	30,088	28,551	25,816
Revenue (₹ Cr)	169	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	32.83	414.00	288.22	-371.81	387.35
Net Margin (%)	18.39	11.23	14.79	-3.93	26.01
RoE (%)	18.93	8.38	29.77	-3.85	25.18
Price to Earnings	14.12	74.83	104.39	--	66.84
Price-To-Book	2.28	6.08	22.41	3.57	14.93

Income Statement (₹ Cr)

	Jenburkt Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	168.73	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	178.48	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	127.92	2,792.00	1,485.56	8,195.15	919.25
EBITDA	40.81	772.00	450.24	1,010.13	542.56
Depreciation	3.03	226.00	50.83	857.51	37.68
EBIT	37.78	546.00	399.41	152.62	504.88
Interest	0.48	217.00	40.84	342.73	3.77
Other Income	9.76	122.00	12.78	244.31	27.45
Exceptional Items	-3.95	12.00	0.00	-216.88	0.00
Profit before Tax	43.11	463.00	371.35	-162.68	528.56
Provision for Tax	10.28	49.00	83.14	209.13	141.21
Profit after Tax	32.83	414.00	288.22	-371.81	387.35

	Jenburkt Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	197.04	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	5.83	1,712.00	202.03	5,044.14	42.40
Current Liabilities	23.15	1,622.00	835.87	4,758.28	230.82
Total Liabilities	225.04	8,578.00	2,326.71	17,723.32	1,983.96

	Jenburkt Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	87.09	5,343.00	519.60	10,211.52	1,026.85
Current Assets	95.09	2,606.00	1,681.81	7,191.66	881.27
Total Assets	225.04	8,578.00	2,326.71	17,723.32	1,983.96
Total Debt*	0.00	2,125.00	259.37	5,495.48	26.49
Net Current Assets	71.94	984.00	845.94	2,433.38	650.46
Contingent Liabilities	17.20	768.26	19.09	95.72	17.25

	Jenburkt Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	26.52	390.00	205.05	1,652.60	292.17
Cash Flow from Investing Activities	-19.45	-241.00	-409.72	-826.03	-265.94
Cash from Financing Activities	-8.86	-54.00	283.07	-38.98	4.10
Net Cash Inflow / Outflow	-1.79	95.00	78.39	787.59	30.33

	Jenburkt Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	25.34	6.79	29.22	1.24	32.42
ROE (%)	18.93	8.38	29.77	-3.85	25.18
ROA (%)	15.55	4.94	24.77	-2.21	21.93
EBIT Margin (%)	22.39	15.32	20.63	1.66	34.54
Net Margin (%)	18.39	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Jenburkt Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	9.08	18.37	46.65	0.78	40.90
EBIT Growth (%)	1.76	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	1.20	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	10.84	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	14.71	13.47	144.31	0.33	26.03

	Jenburkt Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	12.89	76.81	102.79	-91.24	66.84
Price / Book Value	2.28	6.08	22.41	3.57	14.93
Dividend Yield (%)	1.97	0.00	0.08	0.00	0.08
EV/EBITDA	10.06	41.54	66.63	32.36	47.22
Market Cap (₹ Cr)	421.67	19,071.62	12,753.19	18,108.89	20,944.75

	Jenburkt Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	0.31	0.11	0.53	0.02
Short term debt to equity ratio	--	0.09	0.05	0.09	0.02
Current Ratio	4.11	1.61	2.01	1.51	3.82
Quick Ratio	3.52	1.06	1.14	0.87	2.82
Interest Coverage	90.43	3.13	10.09	0.53	141.16

	Jenburkt Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	14.44	16.50	26.28	23.44	24.80
Asset Turnover	0.80	0.43	1.66	0.55	0.83
Receivable days	48.77	58.75	40.13	78.20	88.98
Inventory Days	24.35	75.82	60.29	93.30	56.04
Payable days	106.30	186.21	232.47	226.14	99.95
Cash Conversion Cycle	-33.18	-51.64	-132.04	-54.64	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.